22nd Mar 2023 11:10
Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focusing on sulforaphane-based medicines - Presents top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. Says the study is aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says SFX-01 shows no serious adverse effects and the study is on schedule for full reporting in the second quarter. Read More
